Drug Profile


Alternative Names: (L)-phencynonate; (L)-phencynonate hydrochloride; L-hydrochloric acid phencynonate; L-LPC; L-phencynonate; L-phencynonate hydrochloride; Levo phencynonate hydrochloride; Levophencynonate hydrochloric; LH tablet

Latest Information Update: 04 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Academy of Military Medical Sciences
  • Developer Sihuan Pharmaceutical Holdings Group
  • Class Antiemetics; Aza compounds; Glycolates
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Vertigo

Most Recent Events

  • 04 Apr 2017 Preregistration for Vertigo in China (PO) before April 2017 (Sihuan Pharmaceutical pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top